Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Share this content:
Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Sponsors and Collaborators
Chronic Lymphocytic Leukemia Research Consortium

Celgene Corporation

Contact
Mary Carpenter, CRC

858-822-5635

mcarpenter@ucsd.edu

Danelle F James, MD

858-822-7894

dfjames@ucsd.edu

Principal Investigators
Thomas J Kipps, MD, PhD

Director of the CLL Research Consortium and University of California San Diego
 
Danelle F James, MD, MAS
CLL Research Consortium and University of California San Diego
 
ClinicalTrials.gov Identifier
NCT01199575

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs